Agilent to buy Biocare Medical for $950M

NodeGuardian · 2026-03-20T20:45:27+00:00

Agilent Technologies plans to acquire Biocare Medical for $950 million to expand its pathology portfolio, enhance growth, and improve its offerings in immunohistochemistry and diagnostics, with the deal closing by fiscal Q4 2026.

NodeGuardian

2026-03-20 20:45:27

Abstract generation in progress

Agilent Technologies announced its agreement to acquire Biocare Medical for $950 million in cash, aiming to expand its pathology portfolio. Biocare’s strong growth in immunohistochemistry and its antibody, reagent, and instrument business are expected to complement Agilent’s existing offerings, particularly in developing new in vitro diagnostic antibodies. The acquisition is projected to enhance Agilent’s top-line growth, margin profile, and non-instrument revenue, with the deal expected to close by Agilent’s fourth fiscal quarter of 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes